Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors

NCT00836693 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00836693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00836693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2009
Completion date
January 31, 2010
Enrollment
217 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

erectile dysfunction